Integrating a computational workflow that leverages multi-omics data with a proprietary, humanized in vivo screening platform ...
Members of Medigene management as expert speakers, Prof. Dolores Schendel, Chief Scientific Officer and Kirsty Crame, MD, Vice President, Clinical Strategy & Development Presentations and seminars ...
Hosted on MSN
Engineered T-cells that express both CARs and TCRs can better distinguish between cancerous and healthy tissues
Researchers have developed an innovative dual-receptor T-cell therapy that promises safer and more effective cancer treatments. This study, published in Cell, demonstrates that engineering T-cells to ...
Cancer immunotherapy approaches such as adoptive transfer of chimeric antigen receptor (CAR) T cells or tumor-infiltrating lymphocytes have yielded promising results in hematological malignancies.
Planegg/Martinsried, 22 June 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid ...
Immatics is advancing Anzu-cel, a T-cell receptor therapy for melanoma with potential for significant annual revenue. Learn ...
Researchers at the University of Oslo and Oslo University Hospital have developed a promising new immunotherapy targeting the ...
Its End-to-End Platform generates optimal 3S (sensitive, specific and safe) T cell receptors with unique and distinctive attributes that are utilized in multiple therapeutic modalities, such as T cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback